Praful Kumar Ravi, M.B.,BChir
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Transitional Cell | 5 | 2024 | 808 | 2.130 |
Why?
|
| Urinary Bladder Neoplasms | 10 | 2023 | 2245 | 1.760 |
Why?
|
| Prostate-Specific Antigen | 9 | 2024 | 2494 | 1.730 |
Why?
|
| Prostatic Neoplasms | 18 | 2024 | 11124 | 1.380 |
Why?
|
| Carcinoma, Renal Cell | 9 | 2022 | 3143 | 0.910 |
Why?
|
| Prostatectomy | 10 | 2023 | 1890 | 0.880 |
Why?
|
| Kidney Neoplasms | 10 | 2022 | 4262 | 0.850 |
Why?
|
| Seminoma | 3 | 2023 | 137 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2024 | 9239 | 0.780 |
Why?
|
| Testicular Neoplasms | 4 | 2023 | 804 | 0.720 |
Why?
|
| Cystectomy | 6 | 2021 | 686 | 0.700 |
Why?
|
| Neoadjuvant Therapy | 4 | 2023 | 2728 | 0.690 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2018 | 48 | 0.650 |
Why?
|
| Androgen Antagonists | 6 | 2023 | 1377 | 0.610 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2023 | 1524 | 0.580 |
Why?
|
| Immunoconjugates | 2 | 2023 | 901 | 0.580 |
Why?
|
| Autoantibodies | 1 | 2024 | 2035 | 0.520 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 160 | 0.510 |
Why?
|
| Multiple Myeloma | 3 | 2018 | 5181 | 0.510 |
Why?
|
| Lutetium | 2 | 2023 | 32 | 0.440 |
Why?
|
| Periodicity | 1 | 2014 | 363 | 0.430 |
Why?
|
| Nephrectomy | 5 | 2022 | 1050 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2023 | 11524 | 0.360 |
Why?
|
| Hospitals, Teaching | 2 | 2014 | 1179 | 0.360 |
Why?
|
| Vinblastine | 2 | 2021 | 502 | 0.350 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 1179 | 0.350 |
Why?
|
| Male | 53 | 2024 | 350118 | 0.350 |
Why?
|
| Neoplasm Staging | 6 | 2023 | 11031 | 0.340 |
Why?
|
| Hospital Mortality | 8 | 2015 | 5317 | 0.320 |
Why?
|
| Disease-Free Survival | 5 | 2022 | 6895 | 0.320 |
Why?
|
| Glucocorticoids | 1 | 2017 | 2107 | 0.320 |
Why?
|
| Anemia | 1 | 2017 | 1506 | 0.310 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 501 | 0.310 |
Why?
|
| Prostate | 4 | 2023 | 1774 | 0.310 |
Why?
|
| Myeloma Proteins | 2 | 2018 | 72 | 0.300 |
Why?
|
| Aged, 80 and over | 20 | 2023 | 57776 | 0.300 |
Why?
|
| Deoxycytidine | 2 | 2021 | 826 | 0.290 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 1641 | 0.290 |
Why?
|
| Disease Management | 2 | 2020 | 2459 | 0.290 |
Why?
|
| Cisplatin | 3 | 2022 | 1662 | 0.290 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1832 | 0.270 |
Why?
|
| Aged | 33 | 2024 | 163280 | 0.270 |
Why?
|
| Humans | 64 | 2024 | 744343 | 0.270 |
Why?
|
| Inpatients | 3 | 2013 | 2518 | 0.260 |
Why?
|
| Hospitalization | 3 | 2014 | 10262 | 0.260 |
Why?
|
| Robotics | 4 | 2013 | 899 | 0.250 |
Why?
|
| Doxorubicin | 2 | 2021 | 2234 | 0.250 |
Why?
|
| Postoperative Complications | 12 | 2016 | 15295 | 0.250 |
Why?
|
| Methotrexate | 2 | 2021 | 1727 | 0.240 |
Why?
|
| Treatment Outcome | 20 | 2023 | 63114 | 0.240 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2023 | 50 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 6538 | 0.230 |
Why?
|
| Surgical Procedures, Operative | 1 | 2015 | 1876 | 0.230 |
Why?
|
| Dipeptides | 2 | 2023 | 409 | 0.230 |
Why?
|
| Healthcare Disparities | 3 | 2015 | 3158 | 0.230 |
Why?
|
| Suicide | 1 | 2014 | 1477 | 0.230 |
Why?
|
| Neoplasm Metastasis | 6 | 2021 | 4851 | 0.230 |
Why?
|
| Middle Aged | 30 | 2023 | 213383 | 0.230 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2024 | 182 | 0.220 |
Why?
|
| Heterocyclic Compounds, 1-Ring | 1 | 2023 | 65 | 0.220 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 1540 | 0.220 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2023 | 114 | 0.210 |
Why?
|
| Combined Modality Therapy | 4 | 2020 | 8642 | 0.200 |
Why?
|
| Immunotherapy | 4 | 2020 | 4445 | 0.200 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3748 | 0.200 |
Why?
|
| Disease Progression | 6 | 2022 | 13284 | 0.190 |
Why?
|
| Camptothecin | 1 | 2023 | 576 | 0.180 |
Why?
|
| Teratoma | 1 | 2023 | 395 | 0.180 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2022 | 252 | 0.180 |
Why?
|
| Anxiety | 1 | 2014 | 4297 | 0.180 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 315 | 0.170 |
Why?
|
| Hormones | 1 | 2023 | 889 | 0.160 |
Why?
|
| Taxoids | 3 | 2022 | 666 | 0.160 |
Why?
|
| Proportional Hazards Models | 6 | 2021 | 12354 | 0.160 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2022 | 841 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2023 | 1770 | 0.160 |
Why?
|
| Survival Rate | 3 | 2018 | 12788 | 0.160 |
Why?
|
| Retrospective Studies | 16 | 2023 | 77449 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 890 | 0.150 |
Why?
|
| Adult | 17 | 2023 | 214055 | 0.150 |
Why?
|
| Length of Stay | 7 | 2015 | 6309 | 0.150 |
Why?
|
| United States | 17 | 2023 | 69872 | 0.150 |
Why?
|
| Bone Marrow | 2 | 2018 | 2948 | 0.150 |
Why?
|
| Female | 25 | 2022 | 380194 | 0.150 |
Why?
|
| Muscle, Smooth | 1 | 2021 | 934 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2023 | 1275 | 0.150 |
Why?
|
| Laparoscopy | 3 | 2014 | 2151 | 0.140 |
Why?
|
| Androstenes | 2 | 2016 | 170 | 0.140 |
Why?
|
| Time Factors | 8 | 2021 | 40075 | 0.140 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2022 | 3479 | 0.140 |
Why?
|
| Antigens, Neoplasm | 1 | 2024 | 1988 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2023 | 1061 | 0.130 |
Why?
|
| Internationality | 1 | 2021 | 1003 | 0.130 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 3616 | 0.130 |
Why?
|
| Urinary Bladder | 1 | 2021 | 1172 | 0.120 |
Why?
|
| Androstenols | 1 | 2014 | 25 | 0.120 |
Why?
|
| Orchiectomy | 3 | 2023 | 474 | 0.120 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2013 | 1018 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.120 |
Why?
|
| Risk Factors | 9 | 2021 | 72290 | 0.110 |
Why?
|
| Multivariate Analysis | 7 | 2015 | 12245 | 0.110 |
Why?
|
| Neoplasms | 4 | 2016 | 21683 | 0.110 |
Why?
|
| Lymph Node Excision | 2 | 2023 | 1261 | 0.110 |
Why?
|
| Plasma Cells | 1 | 2016 | 591 | 0.110 |
Why?
|
| Decompression | 1 | 2012 | 43 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2017 | 553 | 0.110 |
Why?
|
| Prognosis | 7 | 2023 | 29063 | 0.110 |
Why?
|
| SEER Program | 2 | 2014 | 1508 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2013 | 137 | 0.110 |
Why?
|
| Intraoperative Complications | 3 | 2013 | 1198 | 0.100 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2012 | 85 | 0.100 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 465 | 0.100 |
Why?
|
| Hospital Charges | 1 | 2013 | 362 | 0.100 |
Why?
|
| Urinary Catheterization | 1 | 2012 | 202 | 0.100 |
Why?
|
| Remission Induction | 1 | 2017 | 2386 | 0.100 |
Why?
|
| Bone Neoplasms | 2 | 2013 | 2529 | 0.100 |
Why?
|
| Radiosurgery | 1 | 2021 | 1329 | 0.100 |
Why?
|
| Kidney Pelvis | 1 | 2012 | 188 | 0.100 |
Why?
|
| Survival Analysis | 3 | 2020 | 10252 | 0.100 |
Why?
|
| Urolithiasis | 1 | 2012 | 131 | 0.100 |
Why?
|
| Cohort Studies | 7 | 2023 | 40561 | 0.090 |
Why?
|
| North America | 1 | 2014 | 1249 | 0.090 |
Why?
|
| Ureteral Obstruction | 1 | 2012 | 296 | 0.090 |
Why?
|
| Odds Ratio | 4 | 2016 | 9849 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2016 | 1534 | 0.090 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2014 | 501 | 0.090 |
Why?
|
| Databases, Factual | 5 | 2019 | 7729 | 0.090 |
Why?
|
| Peptide YY | 1 | 2010 | 130 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2014 | 1654 | 0.090 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2016 | 934 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 3597 | 0.090 |
Why?
|
| Urologic Surgical Procedures | 1 | 2012 | 302 | 0.090 |
Why?
|
| Hospital Administration | 1 | 2013 | 353 | 0.080 |
Why?
|
| Insulin Resistance | 1 | 2023 | 3864 | 0.080 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2924 | 0.080 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 39050 | 0.080 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 13695 | 0.080 |
Why?
|
| Chronic Disease | 1 | 2024 | 9146 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2014 | 1142 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2016 | 961 | 0.080 |
Why?
|
| Logistic Models | 5 | 2014 | 13408 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2013 | 1915 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 2024 | 7880 | 0.070 |
Why?
|
| Puberty | 1 | 2010 | 490 | 0.070 |
Why?
|
| Longitudinal Studies | 1 | 2023 | 13989 | 0.070 |
Why?
|
| Blood Transfusion | 4 | 2015 | 1301 | 0.070 |
Why?
|
| Biopsy | 1 | 2018 | 6756 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2023 | 9274 | 0.070 |
Why?
|
| Urinary Tract Infections | 1 | 2012 | 788 | 0.070 |
Why?
|
| ROC Curve | 1 | 2014 | 3527 | 0.070 |
Why?
|
| Patient Admission | 1 | 2013 | 1380 | 0.070 |
Why?
|
| Androgens | 2 | 2023 | 1281 | 0.070 |
Why?
|
| Human Growth Hormone | 1 | 2010 | 683 | 0.060 |
Why?
|
| Quality of Life | 2 | 2023 | 12804 | 0.060 |
Why?
|
| Pneumonia | 1 | 2016 | 2133 | 0.060 |
Why?
|
| Cross Infection | 1 | 2013 | 1416 | 0.060 |
Why?
|
| Castration | 1 | 2023 | 159 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2015 | 1797 | 0.060 |
Why?
|
| Hospitals | 2 | 2016 | 3952 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5319 | 0.060 |
Why?
|
| Age Factors | 3 | 2014 | 18370 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2014 | 3508 | 0.050 |
Why?
|
| Carcinoma | 1 | 2013 | 2375 | 0.050 |
Why?
|
| Propensity Score | 3 | 2013 | 1781 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 7279 | 0.050 |
Why?
|
| Adolescent | 4 | 2018 | 85781 | 0.050 |
Why?
|
| Melanoma | 1 | 2019 | 5510 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2023 | 53288 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2015 | 3749 | 0.050 |
Why?
|
| Mental Health | 1 | 2014 | 3019 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 629 | 0.040 |
Why?
|
| Risk Assessment | 3 | 2016 | 23338 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2020 | 553 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 371 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 552 | 0.040 |
Why?
|
| Incidence | 2 | 2013 | 20947 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4371 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2023 | 973 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 4253 | 0.040 |
Why?
|
| Mutation | 1 | 2022 | 29786 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 9959 | 0.030 |
Why?
|
| Tubulin Modulators | 1 | 2016 | 110 | 0.030 |
Why?
|
| Young Adult | 3 | 2019 | 56430 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2020 | 492 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2309 | 0.030 |
Why?
|
| Minority Groups | 1 | 2023 | 1223 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5535 | 0.030 |
Why?
|
| Mid-Atlantic Region | 1 | 2013 | 23 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 7659 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2020 | 1613 | 0.030 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2013 | 92 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2013 | 6459 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2013 | 5788 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 2645 | 0.030 |
Why?
|
| Risk | 2 | 2016 | 9687 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 2453 | 0.030 |
Why?
|
| Laparotomy | 1 | 2014 | 473 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2013 | 256 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2015 | 447 | 0.020 |
Why?
|
| New England | 1 | 2013 | 1022 | 0.020 |
Why?
|
| Gastrectomy | 1 | 2015 | 663 | 0.020 |
Why?
|
| Pancreatectomy | 1 | 2015 | 804 | 0.020 |
Why?
|
| Colectomy | 1 | 2015 | 683 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 13102 | 0.020 |
Why?
|
| Hysterectomy | 1 | 2015 | 927 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2014 | 2886 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 4479 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2015 | 1094 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2013 | 1842 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2014 | 1312 | 0.020 |
Why?
|
| Perioperative Care | 1 | 2015 | 1002 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2013 | 2971 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2020 | 11366 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2014 | 1372 | 0.020 |
Why?
|
| Patient Transfer | 1 | 2013 | 761 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2022 | 8428 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 7913 | 0.010 |
Why?
|
| Cost of Illness | 1 | 2013 | 1859 | 0.010 |
Why?
|
| Cause of Death | 1 | 2014 | 3584 | 0.010 |
Why?
|
| Linear Models | 1 | 2013 | 5952 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 2759 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 25043 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 7785 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2013 | 2494 | 0.010 |
Why?
|
| Medicaid | 1 | 2013 | 2736 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2010 | 2585 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 13881 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10397 | 0.010 |
Why?
|
| Comorbidity | 1 | 2013 | 10388 | 0.010 |
Why?
|
| Sepsis | 1 | 2012 | 2593 | 0.010 |
Why?
|
| Medicare | 1 | 2013 | 6566 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2010 | 6256 | 0.010 |
Why?
|
| Child | 1 | 2010 | 77709 | 0.000 |
Why?
|